Blood
01 Jan 2013
A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency
This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples. Official Title A Test to Predict the Hemolytic Potential of Drugs…
Blood
01 Jan 2013
Severe Hemophilia A Study
To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity. Official Title An Open-label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) with Severe…
Blood
01 Jan 2013
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected with HIV
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients’ immune systems react to HIV and anti-HIV drugs. Doctors generally treat patients in…
Blood
01 Jan 2013
Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorder or Myelodysplastic Syndrome
Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy. Sometimes the transplanted cells reject the body’s normal tissues. Alemtuzumab may prevent this from happening. Official Title Phase II Study of Submyeloablative Conditioning Regimen Comprising Low-Dose Total Body Irradiation, Fludarabine,…
Blood
01 Jan 2013
Imatinib Mesylate in Treating Patients With Myelofibrosis
Imatinib mesylate may stop the growth of myelofibrosis by blocking certain enzymes necessary for cell growth. Official Title Phase II Study of Imatinib Mesylate in Patients With Myelofibrosis Conditions – Polycythemia Vera- chronic idiopathic myelofibrosis- Essential Thrombocythemia- Chronic Myelomonocytic Leukemia Study Type Interventional Study Design Treatment Further Details OBJECTIVES:Determine the…
Blood
01 Jan 2013
Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes
OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle cell syndromes. OBJECTIVES: Determine the effectiveness of the combined use of clotrimazole and hydroxyurea on a specific panel of red cell characteristics in patients with sickle…
Blood
01 Jan 2013
Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia
Patients with sickle cell disease have abnormal hemoglobin (the protein in red blood cells that carries oxygen to the body). This abnormality causes red blood cells to take on a sickle shape, producing disease symptoms. Fetal hemoglobin, a type of hemoglobin present in fetuses and babies, can prevent red cells…
Blood
01 Jan 2013
Magnetic Resonance Imaging of the Blood Vessels of the Heart
This study is directed at evaluating patients with “myocardial ischemia” or poor blood supply to the heart muscle due to coronary artery disease. The major objective of this study is to determine the level of safety and effectiveness of magnetic resonance imaging at diagnosing coronary artery disease. In addition, this…
Blood
01 Jan 2013
Study of Combination Thalidomide Plus Glucocorticoid Therapy Versus Glucocorticoid Therapy Alone as Induction Therapy for Previously Untreated Subjects with Multiple Myeloma
Randomized subjects will receive study drug, either thalidomide plus high-dose dexamethasone or placebo identical in appearance to thalidomide plus high-dose dexamethasone, in 4-week cycles. Subjects will remain on study drug until they experience disease progression or until the subject discontinues for any other reason. Subjects will have visits every cycle…
